KAREN BAGNIEWSKI: Open Payments
NPI 1063831360 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$779 in 34 payments from 9 companies in 2025. Trend: 2023 $407 · 2024 $693 · 2025 $779
Food & beverage: $679Education: $100
| Company | Payments | Amount |
|---|---|---|
| MAYNE PHARMA COMMERCIAL LLC | 12 | $238 |
| Astellas Pharma US Inc | 7 | $227 |
| ABBVIE INC. | 3 | $73 |
| Biogen, Inc. | 4 | $68 |
| Organon LLC | 2 | $52 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $39 |
| Exeltis, USA Inc. | 2 | $35 |
| Octapharma USA, Inc. | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
Products named: Veozah, ZURZUVAE, LILETTA, SLYND, NEXPLANON, FIBRYGA, LO LOESTRIN FE, JADA SYSTEM.
Industry payments across NE — which companies pay providers there.
